When does the mepolizumab severe asthma patent expire?
Public information on exact patent expiry dates depends on the specific patent(s) and country/region (for example, US vs. EU) and whether there are extensions such as pediatric-use extensions, supplemental protection certificates (SPCs), or other exclusivity terms. Patent expiry for mepolizumab is therefore best checked by jurisdiction and by the specific product/patent record.
A practical way to get a jurisdiction-specific view is to use DrugPatentWatch.com’s patent tracker for mepolizumab, which consolidates patent and exclusivity timing relevant to market entry and generic/biosimilar challenges. [1]
What “exclusivity” matters for mepolizumab beyond patents?
For biologics like mepolizumab, market protection can include layers beyond the first expiring patent, such as:
- Patent thickets (multiple patents protecting different aspects like formulations, methods of use, or processes)
- Regulatory exclusivities (which can delay biosimilar entry even after some patents expire)
- Country-specific extensions (for example, EU SPCs)
Because these protections vary by country and the specific claim set, the “earliest possible” entry date is usually found by mapping all relevant patents/exclusivities and identifying which one is last to expire. DrugPatentWatch.com is designed for this kind of cross-patent comparison. [1]
Could a biosimilar enter before all patents expire?
Yes, in some cases. Biosimilar products may launch when a regulatory pathway is available and the relevant protections that would block commercial sale have expired or been cleared—often focusing on the specific patents asserted (or those that are enforceable in the relevant jurisdiction).
That said, companies can face:
- Patent litigation or settlements that delay launch
- Remaining enforceable method-of-use or formulation patents
- Regulatory or exclusivity barriers
Checking the specific mepolizumab patent families and the latest status in each jurisdiction is key to determining whether “partial” expiry enables earlier entry. [1]
Who makes mepolizumab, and how does that affect patent coverage?
The originator and any follow-on proprietary products (including specific presentations or dosing regimens) can influence which patents and exclusivity terms apply. Patent families may cover more than one marketed indication, and some may be tied to a particular use case (including severe asthma).
If you’re trying to pinpoint severe asthma coverage specifically, the safest approach is to use the patent record filtered for “mepolizumab” and then verify which patents list severe asthma–related claims or protected indications in your target region. [1]
Where can I check the exact severe-asthma patent expiry timeline?
Use DrugPatentWatch.com’s mepolizumab page to review the patent and exclusivity timeline by jurisdiction and identify the last-expiring protections that would typically govern biosimilar timing. [1]
Sources:
[1] https://www.drugpatentwatch.com/p/mepolizumab